Portal de Periódicos da CAPES

The Electrophysiology and Pharmacology of Verapamil, Flecainide, and Amiodarone: Correlations with Clinical Effects and Antiarrhythmic Actions a

1984; Wiley; Volume: 432; Issue: 1 Linguagem: Inglês

10.1111/j.1749-6632.1984.tb14522.x

1749-6632

Bramah N. Singh, Koonlawee Nademanee, Martin A. Josephson, Nobuo Ikeda, Nagammal Venkatesh, Ramaswamy Kannan,

Cardiac pacing and defibrillation studies

Annals of the New York Academy of SciencesVolume 432, Issue 1 p. 210-235 The Electrophysiology and Pharmacology of Verapamil, Flecainide, and Amiodarone: Correlations with Clinical Effects and Antiarrhythmic Actionsa BRAMAH N. SINGH M.D., Corresponding Author BRAMAH N. SINGH M.D. Department of Cardiology Wadsworth Veterans Administration Hospital; and Department of Medicine UCLA School of Medicine Los Angeles, California 90024bSection of Cardiology 691/ 111E, Wadsworth Veterans Administration Hospital, Wilshire and Sawtelle Boulevards, Los Angeles, California 90073.Search for more papers by this authorKOONLAWEE NADEMANEE, KOONLAWEE NADEMANEE Department of Cardiology Wadsworth Veterans Administration Hospital; and Department of Medicine UCLA School of Medicine Los Angeles, California 90024Search for more papers by this authorMARTIN A. JOSEPHSON, MARTIN A. JOSEPHSON Department of Cardiology Wadsworth Veterans Administration Hospital; and Department of Medicine UCLA School of Medicine Los Angeles, California 90024Search for more papers by this authorNOBUO IKEDA, NOBUO IKEDA Department of Cardiology Wadsworth Veterans Administration Hospital; and Department of Medicine UCLA School of Medicine Los Angeles, California 90024Search for more papers by this authorNAGAMMAL VENKATESH, NAGAMMAL VENKATESH Department of Cardiology Wadsworth Veterans Administration Hospital; and Department of Medicine UCLA School of Medicine Los Angeles, California 90024Search for more papers by this authorRAMASWAMY KANNAN, RAMASWAMY KANNAN Department of Cardiology Wadsworth Veterans Administration Hospital; and Department of Medicine UCLA School of Medicine Los Angeles, California 90024Search for more papers by this author BRAMAH N. SINGH M.D., Corresponding Author BRAMAH N. SINGH M.D. Department of Cardiology Wadsworth Veterans Administration Hospital; and Department of Medicine UCLA School of Medicine Los Angeles, California 90024bSection of Cardiology 691/ 111E, Wadsworth Veterans Administration Hospital, Wilshire and Sawtelle Boulevards, Los Angeles, California 90073.Search for more papers by this authorKOONLAWEE NADEMANEE, KOONLAWEE NADEMANEE Department of Cardiology Wadsworth Veterans Administration Hospital; and Department of Medicine UCLA School of Medicine Los Angeles, California 90024Search for more papers by this authorMARTIN A. JOSEPHSON, MARTIN A. JOSEPHSON Department of Cardiology Wadsworth Veterans Administration Hospital; and Department of Medicine UCLA School of Medicine Los Angeles, California 90024Search for more papers by this authorNOBUO IKEDA, NOBUO IKEDA Department of Cardiology Wadsworth Veterans Administration Hospital; and Department of Medicine UCLA School of Medicine Los Angeles, California 90024Search for more papers by this authorNAGAMMAL VENKATESH, NAGAMMAL VENKATESH Department of Cardiology Wadsworth Veterans Administration Hospital; and Department of Medicine UCLA School of Medicine Los Angeles, California 90024Search for more papers by this authorRAMASWAMY KANNAN, RAMASWAMY KANNAN Department of Cardiology Wadsworth Veterans Administration Hospital; and Department of Medicine UCLA School of Medicine Los Angeles, California 90024Search for more papers by this author First published: December 1984 https://doi.org/10.1111/j.1749-6632.1984.tb14522.xCitations: 8 a This work was supported by grants from the Medical Research Service of the Veterans Administration and from the American Heart Association (the Greater Los Angeles affiliate). AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Ellrodt, G., C. Y. C. Chew & B. N. Singh. 1980. Therapeutic indications of slow-channel blockade in cardiocirculatory disorders. Circulation 62: 669– 679. 2 Hellestrandt, K. J., R. S. Bexton, A. W. Nathan, R. A. J. Spurrell & A. J. Camm. 1982. Acute flecainide acetate on cardiac conduction and refractoriness in man. Brit. Heart J. 48: 140– 148. 3 Anderson, J. L., J. R. Stewart & B. A. Perry. 1981. Oral flecainide acetate for the treatment of ventricular arrhythmias. N. Engl. J. Med. 305: 474– 477. 4 Singh, B. N. 1983. Amiodarone: Historical development and pharmacologic profile. Am. Heart J. 106: 788– 797. 5 Singh, B. N. & E. M. Vaughan Williams. 1972. A fourth class of antidysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials and on other features of cardiac function. Cardiovasc. Res. 6: 109– 114. 6 Cranefield, P. F., R. S. Aronson & A. L. Wit. 1976. Effect of verapamil on the normal action potential and on a calcium-dependent slow response of canine cardiac Purkinje fibers. Circulation Res. 34: 204– 213. 7 Rosen, M. R., A. L. Wit & B. F. Hoffman. 1975. Appraisal and reappraisal of cardiac therapy: Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamil. Am. Heart J. 89: 655– 673. 8 Tritthart, H. A. 1980. Pharmacology and electrophysiology of calcium antagonists. Clin. Invest. Med. 3: 1– 7. 9 Haeusler, G. 1972. Differential effect on verapamil on excitation-contraction coupling in smooth muscle and on excitation-secretion coupling in adrenergic terminals. J. Pharmacol. Exp. Ther. 180: 672– 679. 10 Harder, D. R., L. Belardinelli, N. Sperelakis, R. Rubio & R. M. Berne. 1979. Differential effects of adenosine and nitroglycerin on the action potentials of large and small coronary arteries. Circ. Res. 44. 176– 182. 11 Singh, B. N., H. S. Hecht & K. Nademanee. 1982. Electrophysiologic and hemodynamic actions of slow-channel blocking compounds. Prog. Cardiovasc. Dis. 25: 103– 132. 12 Chew, C. Y. C., H. S. Hecht, J. T. Collet, R. G. McAllister & B. N. Singh. 1981. Iduence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease. Am. J. Cardiol. 47: 917– 922. 13 Chew, C. Y. C., G. B. Brown, B. N. Singh, M. M. Wong, C. Pierce & R. Peter-Sen. 1983. Effects of verapamil on coronary hemodynamic function and vasomobility relative to its mechanism of antianginal action. Am. J. Cardiol. 51: 661– 918. 14 Brown, G. B., C. D. Pierce, R. B. Peterson, B. N. Singh, E. L. Bolson & H. T. Dodge. 1981. Verapamil, a mild coronary dilator, inhibits sympathetic and ergonovine-induced coronary constriction in humans (abstract). Circulation.(Suppl. IV-VI): 150. 15 Spear, J. F., L. N. Horowitz, A. B. Hodess, H. Macvaugh & E. N. Moore. Cellular electrophysiology of human myocardial infarction. Abnormalities of cellular activation. Circulation 59: 247– 256. 16 Wit, A. L. & P. F. Cranefield. 1981. Triggered activity in cardiac muscle fibers of the simian mitral valve. Circulation Res. 38: 85– 94. 17 Kawai, C., T. Konishi, E. Matsuyama & H. Okazaki. 1981. Comparative effects of three calcium antagonists, diltiazem, verapamil and nifedipine, on the sino-atrial and atrioventricular nodes. Experimental and clinical studies. Circulation 63: 1035. 18 Zipes, D. P. & J. C. Fischer. 1974. Effects of agents which inhibit the slow channel automaticity and atrioventricular conduction in the dog. Circ. Res. 34: 184– 192. 19 Okada, T. 1976. Effect of verapamil on electrical activities of SA node, ventricular muscle and Purkinje fibers in isolated rabbit hearts. Jpn. Circ. J. 40: 329– 341. 20 Singh, B. N., G. Ellrodt & C. T. Peter. 1978. Verapamil: A review of its pharmacological properties and therapeutic uses. Drugs 15: 169– 197. 21 Singh, B. N., K. Nademanee & S. H. Baky. 1983. Calcium antagonists: Clinical use in the treatment of cardiac arrhythmias. Drugs 25: 125– 153. 22 Sung, R., B. Elser & R. G. McAllister. 1980. Intravenous verapamil for termination of re-entrant supraventricular tachycardias. Intracardiac studies correlated with plasma verapamil concentrations. Ann. Intern. Med. 93: 682– 689. 23 Rinkenberger, R. L., E. N. Prystowsky, J. J. Heger, P. J. Troup, W. M. Jack-man & D. P. Zipes. 1980. Effects of intravenous and oral verapamd administration in patients with supraventricular tachyarrhythmias. Circulation 62: 996– 1010. 24 Storstein, O. & K. Rasmussen. 1974. Digitalis and atrial tachycardia with block. Br. Heart J. 36: 171– 176. 25 Tonkin, A. M., P. E. Aylward & S. E. Joel. 1980. Verapamil in prophylaxis of paroxysmal atrioventricular nodal reentrant tachycardia. J. Cardiovasc. Pharmacol. 2: 473– 480. 26 Klein, G. J., S. Gulamhussein & E. N. Prystowsky. 1981. Comparison of the electrophysiologic effects of intravenous and oral verapamil in patients with paroxysmal supraventricular tachycardia. Am. J. Cardiol. 49: 117– 124. 27 Klein, H. D., H. Pauzner, E. D. Segni, D. David & E. Kaplinsky. 1979. The beneficial effects of verapamil in chronic atrial fibrillation. Arch. Intern. Med. L39: 747– 749. 28 Klein, H. O., R. Lang, E. Weiss, E. Desegni, C. Libhaber, J. Guerrero & E. Kaplinsky. 1982. The influence of verapamil on serum digoxin concentration. Circulation 65: 998– 1003. 29 Gulam Hussein, S., P. Ko, S. G. Carruthers & G. J. Klein. 1982. Accleration of the ventricular response during atrial fibrillation in the Worn-Parkinson-White syndrome after verapamil. Circulation 65: 348– 354. 30 Lazzara, R. & B. Scherlag. 1980. The treatment of arrhythmias by blocking slow current. Ann. Intern. Med. 93: 919– 920. 31 Schmid, J. F., B. D. Seeback, C. L. Henrie, E. H. Banitt & D. C. Kvam. 1975. Some antiarrhythmic actions of a new compound, R-818, in dogs and mice. Fed. Proc. 34: 775. 32 Verdouw, P. D., W. D. Jaap & J. C. Gordon. 1979. Antiarrhythmic and hemodynamic actions of flecainide acetate (R-818) in the ischemic porcine heart. J. Car-diovasc. Pharmacol. 1: 473– 486. 33 Hodess, A. B., W. P. Follansbee, J. F. Spear & E. N. Moore. 1979. Electrophysiological effects of a new antiarrhythmic agent, flecainide, on the intact canine heart. J. Cardiovasc. Pharmacol. 1: 427– 439. 34 Ikeda, N., B. N. Singh, L. D. Davis & O. Hauswirth. 1984. Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers. J. Am. Coll. Cardiol. Submitted for publication. 35 Josephson, M. A., N. Ikeda & B. N. Singh. 1984. Effects of flecainide on ventricular function: clinical and experimental correlations. Am. J. Cardiol. 53: 95B– 100B. 36 Cowan, J. C. & E. M. Vaughan Williams. 1981. Characterization of a new oral antiarrhythmic drug, flecainide R-818. Eur. J. Pharmacol. 73: 333– 342. 37 Borchard, U. & M. Boisten. 1982. Effect of flecainide on action potentials and alternating current-induced arrhythmias in mammalian myocardium. J. Cardiovasc. Pharmacol. 4: 205– 212. 38 Schulze, J. J. & J. Knops. 1982. Effects of flecainide on contractile force and electro-physiological parameters in cardiac muscle. Arzneim. Forsch. 32: 1025– 1029. 39 Hauswirth, O. & B. N. Singh. 1978. Ionic mechanisms in heart muscle in relation to the genesis and pharmacological control of cardiac arrhythmias. Pharmacol. Rev. 30: 5– 63. 40 Singh, B. N., J. R. Collet & C. Y. C. Chew. 1975. New perspectives in the pharmacologic therapy of cardiac arrhythmias. Prog. Cardiovasc. Dis. 22: 243– 301. 41 Vaughan Williams, E. M. 1975. Classification of antidysrhythmic drugs. Pharmacol. Ther. B1: 115– 138. 42 Olsson, S. B. & N. Edvardsson. 1981. Clinical electrophysical study of antiarrhythmic properties of flecainide: Acute intraventricular delayed conduction and prolonged repolarization in regular paced and premature beats using intracardiac monophasic action potentials with programmed stimulation. Am. Heart J. 102: 864– 871. 43 Bextan, R. S., K. J. Hellestrandt, A. W. Nathan, R. A. J. Spurrel & A. J. Camm. 1983. A comparison of the antiarrhythmic effects on AV junctional reentrant tachycardia of oral and intravenous flecainide acetate. Eur. Heart J. 4: 92– 102. 44 Duran, D., E. V. Platia, L. S. C. Griffith, G. Adhar & P. R. Reid. 1982. Suppression of complex ventricular arrhythmias by oral flecainide. Clin. Pharmacol. Ther. 32: 554– 561. 45 Somani, P. 1980. Antiarrhythmic effects of flecainide. Clin. Pharmacol. Ther. 27: 464– 470. 46 Duff, H. J., D. M. Roden, R. J. Maffucci, B. S. Vesper, G. J. Conard, S. B. Higgins, J. A. Oates, R. F. Smith & R. J. Woosley. 1981. Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. Am. J. Cardiol. 48: 1133– 1140. 47 Conard, G. J., G. L. Carlson, J. W. Frost & R. E. Ober. 1979. Human plasma pharmacokinetics, a new antiarrhythmic, following single oral and intravenous doses (abstract). Clin. Pharmacol. Ther. 25: 218. 48 Muhiddin, K. A., K. J. Hellestrandt, A. Nathan, R. Bexton & A. J. Camm. 1982. The electrophysiologic effects of flecainide acetate (R-818) on the cardiac conducting system. Br. J. Clin. Pharmacol. 13 (2): 286P. 49 Conard, G. J., G. E. Cranheim & H. W. Klempt. 1982. Relationship between plasma concentrations and suppression of ventricular extrasystoles by flecainide acetate (R-818) a new antiarrhythmic, in patients. Artzneim. Forsch. 32 (2): 155– 160. 50 The Flecainide-Quinidine Research Group. 1983. Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial. Circulation 67: 1117– 1123. 51 Muhiddin, K., A. W. Nathan, K. J. Hellestrandt, S. O. Banim & A. J. Camm. 1982. Ventricular tachycardia associated with flecainide. Lancet 2: 1220– 1221. 52 Charlier, R., G. Deltour, A. Baudine & F. Chaillet. 1968. Pharmacology of amiodarone, an anti-anginal drug with a new biological profile. Artzneim. Forsch. 18: 1408– 1417. 53 Singh, B. N. 1971. A study of the pharmacological actions of certain drugs and hormones with a particular reference to cardiac muscle. D. Phil. thesis, University of Oxford, England. 54 Singh, B. N. & E. M. Vaughan Williams. 1970. The effect of amiodarone, a new antianginal drug, on cardiac muscle. Br. J. Pharmacol. 39: 657– 667. 55 Rosenbaum, M. B., P. A. Chiale, D. Ryba & M. V. Elizari. 1974. Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride. Am. J. Cardiol. 34: 215– 223. 56 Rosenbaum, M. B., P. A. Chiale & M. S. Halpern. 1976. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am. J. Cardiol. 38: 934– 944. 57 Nademanee, K., J. A. Hendrickson, D. S. Cannom, B. N. Goldreyer & B. N. Singh. 1981. Control of refractory life-threatening ventricular arrhythmias by amiodarone. Am. Heart J. 101: 759– 765. 58 Nademanee, K., J. A. Hendrickson, R. Kannan & B. N. Singh. 1982. Electro-physiological effects of amiodarone in patients with life-threatening ventricular arrhythmias: Modification of induced ventricular tachycardia versus suppression of spontaneously occurring tachyarrhythmias. Am. Heart J. 103: 956– 959. 59 Nademanee, K., B. N. Singh, J. A. Hendrickson, A. W. Reed, S. Melmed & J. M. Hershman. 1982. Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: A potential method for monitoring chronic drug therapy. Circulation 66: 202– 211. 60 Heger, J. J., E. Prystowsky, W. M. Jackman, G. V. Nacarelli, K. A. Warfel, R. L. Rinkenberger & D. P. Zipes. 1981. Amiodarone: Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. New Engl. J. Med. 305: 539– 545. 61 Kaski, J. C., L. A. Firotti, T. Messuti, B. Rubltzky & M. B. Rosenbaum. 1981. Long-term management of sustained recurrent symptomatic ventricular tachycardia with amiodarone. Circulation 64: 273– 280. 62 Podrid, P. J. & B. Lown. 1981. Amiodarone therapy in symptomatic, sustained, refractory, atrial and ventricular tachyarrhythmias. Am. Heart J. 101: 374– 379. 63 Ikeda, N., K. Nademanee, R. Kannan & B. N. Singh. 1984. Electrophysiologic effects of amiodarone: experimental and clinical observations relative to serum and tissue drug concentrations. Am. Heart J. In press. 64 Brugada, P., D. Roy, F. W. Barr, B. Heddle, W. R. Dassen & H. J. J. Wellens. 1982. Electrophysiological effects of intravenous amiodarone (abstract). Am. J. Cardiol. 49: 1044. 65 Nademanee, K., G. Feld, J. A. Hendrickson, V. Intarachot, R. Kannan & B. N. Singh. 1983. Does intravenous amiodarone shorten the latency of the onset of antiarrhythmic action of oral amiodarone in ventricular arrhythmias? J. Am. Coll. Cardiol. 1: 360. 66 Kannan, R., K. Nademanee, J. A. Hendrickson, H. J. Rostami & B. N. Singh. 1982. Amiodarone kinetics after oral doses. Clin. Pharmacol. Ther. 31: 438– 444. 67 Melmed, S., K. Nademanee, A. W. Reed, J. A. Hendrickson, B. N. Singh & J. M. Hershman. 1981. Hyperthyroxinemia with bradycardia and normal thyrotro-pin secretion following chronic amiodarone administration. J. Clin. Endoctrinol. Metab. 53: 997– 1002. 68 Cote, P., M. G. Bourassa, J. Delaye, J. Janin, R. Frement & P. David. 1979. Effects of amiodarone on cardiac hemodynamics and/or myocardial metabolism in patients with coronary artery disease. Circulation 59: 1165– 1172. 69 Polster, P. & J. Broekhuysen. 1976. The adrenergic antagonism of amiodarone. Biochem. Phannacol. 25: 131– 136. 70 Charlier, R. 1970. Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors. Br. J. Pharmacol. 39: 668– 676. 71 Rutitzsky, B., A. L. Giroth & M. B. Rosenbaum. 1982. Efficacy of chronic amiodarone therapy in patients with variant angina and inhibition of ergonovine coronary constriction. Am. Heart J. 103: 38– 44. 72 Deboer, L. W. V., J. J. Nosta, R. A. Kloner & E. Braunwald. 1982. Studies of amiodarone during experimental myocardial infarction: Beneficial effects on hemo-dynamics and infarct size. Circulation 65: 508– 514. 73 Freedberg, A. S., J. G. Papp & E. M. Vaughan Williams. 1970. The effect of altered thyroid state on atrial intracellular potentials. J. Physiol. 207: 357– 363. 74 Pritchard, D. A., B. N. Singh & P. J. Hurley. 1975. Effects of amiodarone on thyroid function in patients with ischemic heart disease. Br. Heart J. 37: 856– 861. 75 Olsson, S. B., L. Brorson & E. Varnauskas. 1973. Class III antiarrhythmic action in man. Observations from monophasic action potential recordings and amiodarone treatment. Br. Heart J. 35: 1255– 1259. 76 Boppana, V. K., S. Shoshani, S. J. Spielman, B. Belhassen & L. N. Horowitz. 1983. Steady state amiodarone and metabolite concentration—relationship to dosage and side effects. J. Am. Coll. Cardiol. 1: 630. 77 Marcus, F. I. 1983. Drug interactions with amiodarone. Am. Heart J. 106: 924– 930. 78 Mosey, J. O., N. S. U. Jaggarao, E. W. Grundy & D. A. Chamberlain. 1981. Amiodarone increases plasma digoxinconcentrations. Br. Heart J. 282: 272– 273. 79 Nademanee, K., R. Kannan, J. A. Hendrickson, M. Burnam, I. Kay & B. N. Singh. 1982. Amiodarone-digoxin interaction during treatment of resistant cardiac arrhythmias (abstract). Am. J. Cardiol. 49: 1026. 80 Venkatesh, N., L. Al-Sarraf, R. Kannan & B. N. Singh. 1983. Tissue-serum correlates of digoxin-amiodarone interaction? Selective drug accumulation as a basis for neurotoxicity during combination therapy. J. Am. Coll. Cardiol. Submitted for publication. 81 Nademanee, K., B. N. Singh, J. A. Hendrickson, V. Intarachot, V. Lopez, G. Feld, D. S. Cannom & J. N. Weiss. 1983. Amiodarone in refractory life-threatening ventricular arrhythmias. Ann. Intern. Med. 98: 577– 584. Citing Literature Volume432, Issue1Clinical Pharmacology of Cardiac Antiarrhythmic Agents: Classical and Current ConceptsDecember 1984Pages 210-235 ReferencesRelatedInformation